DCA’s potential in oncology has been studied for nearly two decades. Understanding what the research actually shows — and what it doesn’t — is essential for anyone researching this compound.

In 2007, Dr. Evangelos Michelakis and colleagues at the University of Alberta published a landmark paper in Cancer Cell showing that DCA caused regression of human non-small cell lung cancer tumours in both in vitro and animal models. The mechanism was clear: DCA reactivated mitochondrial metabolism in cancer cells, triggering apoptosis through increased reactive oxygen species production.

Since then, DCA has been studied across multiple cancer types including glioblastoma, breast cancer, colorectal cancer, B-cell chronic lymphocytic leukaemia, and cervical cancer. Results in cell studies and animal models have been consistently promising.

Human clinical data is more limited. A 2010 phase I trial in glioblastoma patients showed disease stabilisation in some patients. A 2013 case series reported significant tumour regression in five patients across different cancer types. These are encouraging signals, but not the same as large randomised controlled trials.

DCA is not an approved cancer treatment in any jurisdiction. The research is ongoing. What the science shows is a plausible, well-understood mechanism and consistent preclinical results. What it does not yet show is the large-scale human trial data required for clinical approval.

This article is for informational and educational purposes only. AuraDCA products are intended for research use only.